Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
- Conditions
- Fatty Liver DiseaseHIV Infections
- Interventions
- Drug: Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 75
- Registration Number
- NCT05898841
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Infanta Sofía, Madrid, Spain
🇪🇸Hospital Universitario Gregorio Marañon, Madrid, Spain
Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 84
- Registration Number
- NCT05549180
- Locations
- 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain
🇪🇸CHUAC, Coruña, Spain
🇪🇸Hospital Universitario La Princesa, Madrid, Spain
Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)
- Conditions
- HIV Infections
- Interventions
- Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 100
- Registration Number
- NCT05405751
- Locations
- 🇪🇸
H. Infanta Leonor, Madrid, Spain
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:
- Conditions
- HIV-1-infection
- Interventions
- Drug: Dolutegravir/Lamivudine as a single pillDrug: Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 554
- Registration Number
- NCT04884139
- Locations
- 🇪🇸
H. Infanta Leonor, Madrid, Spain
🇪🇸H. La Princesa, Madrid, Spain
🇪🇸H. Univ. La Paz, Madrid, Spain
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 121
- Registration Number
- NCT04880785
- Locations
- 🇪🇸
H. Infanta Leonor, Madrid, Spain
🇪🇸H. Álvaro Cunqueiro, Vigo, Pontevedra, Spain
🇪🇸H. General de Alicante, Alicante, Spain
Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 495
- Registration Number
- NCT04445272
- Locations
- 🇪🇸
Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain
🇪🇸Hospital Universitario Marqués Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Clínic i Provincial Barcelona, Barcelona, Spain
Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain
- Conditions
- Covid19
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 4035
- Registration Number
- NCT04355871
- Locations
- 🇪🇸
H. Univ. de la Ribera, Alzira, Spain
🇪🇸H. Clinica Univ. Navarra, Pamplona, Spain
🇪🇸H. Univ. Menez Rafael Mendez, Lorca, Spain
A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection
- Conditions
- HIV Infections
- Interventions
- Drug: Triple therapyDrug: Dual Therapy
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 141
- Registration Number
- NCT04076423
- Locations
- 🇪🇸
Hospital San Pedro, Logroño, La Rioja, Spain
🇪🇸Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain
🇪🇸Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
- Conditions
- Clostridium Difficile Infection
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 869
- Registration Number
- NCT04075422
- Locations
- 🇪🇸
Hospital Gregorio Marañon, Madrid, Spain
🇪🇸Hospital Univ. Puerta de HIerro, Madrid, Spain
🇪🇸Hospital Clinico San Carlos, Madrid, Spain
A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 50
- Registration Number
- NCT03693508
- Locations
- 🇪🇸
H. Ramón y Cajal, Madrid, Spain
🇪🇸H. Doce de Octubre, Madrid, Spain
🇪🇸Hospital Infanta Leonor, Madrid, Spain